269 related articles for article (PubMed ID: 18927431)
101. BCL6 is a context-dependent mediator of the glioblastoma response to irradiation therapy.
Tribe AKW; Peng L; Teesdale-Spittle PH; McConnell MJ
Int J Biol Macromol; 2024 Jun; 270(Pt 1):131782. PubMed ID: 38734343
[TBL] [Abstract][Full Text] [Related]
102. Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6
Huckvale R; Harnden AC; Cheung KJ; Pierrat OA; Talbot R; Box GM; Henley AT; de Haven Brandon AK; Hallsworth AE; Bright MD; Akpinar HA; Miller DSJ; Tarantino D; Gowan S; Hayes A; Gunnell EA; Brennan A; Davis OA; Johnson LD; de Klerk S; McAndrew C; Le Bihan YV; Meniconi M; Burke R; Kirkin V; van Montfort RLM; Raynaud FI; Rossanese OW; Bellenie BR; Hoelder S
J Med Chem; 2022 Jun; 65(12):8191-8207. PubMed ID: 35653645
[TBL] [Abstract][Full Text] [Related]
103. B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.
Ci W; Polo JM; Melnick A
Curr Opin Hematol; 2008 Jul; 15(4):381-90. PubMed ID: 18536578
[TBL] [Abstract][Full Text] [Related]
104. Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor.
Mamai A; Chau AM; Wilson BJ; Watson ID; Joseph BB; Subramanian PR; Morshed MM; Morin JA; Prakesch MA; Lu T; Connolly P; Kuntz DA; Pomroy NC; Poda G; Nguyen K; Marcellus R; Strathdee G; Theriault B; Subramaniam R; Mohammed M; Abibi A; Chan M; Winston J; Kiyota T; Undzys E; Aman A; Austin N; Du Jardin M; Packman K; Phillippar U; Attar R; Edwards J; O'Meara J; Uehling DE; Al-Awar R; Privé GG; Isaac MB
ACS Med Chem Lett; 2023 Feb; 14(2):199-210. PubMed ID: 36793435
[TBL] [Abstract][Full Text] [Related]
105. Hit-and-run lymphomagenesis by the Bcl6 oncogene.
Green MR; Vicente-Dueñas C; Alizadeh AA; Sánchez-García I
Cell Cycle; 2014; 13(12):1831-2. PubMed ID: 24867153
[No Abstract] [Full Text] [Related]
106. Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays.
Pierrat OA; Liu M; Collie GW; Shetty K; Rodrigues MJ; Le Bihan YV; Gunnell EA; McAndrew PC; Stubbs M; Rowlands MG; Yahya N; Shehu E; Talbot R; Pickard L; Bellenie BR; Cheung KJ; Drouin L; Innocenti P; Woodward H; Davis OA; Lloyd MG; Varela A; Huckvale R; Broccatelli F; Carter M; Galiwango D; Hayes A; Raynaud FI; Bryant C; Whittaker S; Rossanese OW; Hoelder S; Burke R; van Montfort RLM
Sci Rep; 2022 Nov; 12(1):18633. PubMed ID: 36329085
[TBL] [Abstract][Full Text] [Related]
107. Predicting implantation failure: to BCL6 or not to BCL6.
Kosturakis AK; Ryan GL
Fertil Steril; 2022 Feb; 117(2):359. PubMed ID: 35125178
[No Abstract] [Full Text] [Related]
108. Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.
Davis OA; Cheung KJ; Brennan A; Lloyd MG; Rodrigues MJ; Pierrat OA; Collie GW; Le Bihan YV; Huckvale R; Harnden AC; Varela A; Bright MD; Eve P; Hayes A; Henley AT; Carter MD; McAndrew PC; Talbot R; Burke R; van Montfort RLM; Raynaud FI; Rossanese OW; Meniconi M; Bellenie BR; Hoelder S
J Med Chem; 2022 Jun; 65(12):8169-8190. PubMed ID: 35657291
[TBL] [Abstract][Full Text] [Related]
109. Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.
Teng M; Ficarro SB; Yoon H; Che J; Zhou J; Fischer ES; Marto JA; Zhang T; Gray NS
ACS Med Chem Lett; 2020 Jun; 11(6):1269-1273. PubMed ID: 32551010
[TBL] [Abstract][Full Text] [Related]
110. Antilymphoma therapy with a Bcl-6 inhibitor.
McLaughlin P
Curr Hematol Malig Rep; 2009 Oct; 4(4):183-4. PubMed ID: 20425405
[No Abstract] [Full Text] [Related]
111. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.
Cerchietti LC; Ghetu AF; Zhu X; Da Silva GF; Zhong S; Matthews M; Bunting KL; Polo JM; Farès C; Arrowsmith CH; Yang SN; Garcia M; Coop A; Mackerell AD; Privé GG; Melnick A
Cancer Cell; 2010 Apr; 17(4):400-11. PubMed ID: 20385364
[TBL] [Abstract][Full Text] [Related]
112. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
[TBL] [Abstract][Full Text] [Related]
113. The transcriptional modulator BCL6 as a molecular target for breast cancer therapy.
Walker SR; Liu S; Xiang M; Nicolais M; Hatzi K; Giannopoulou E; Elemento O; Cerchietti L; Melnick A; Frank DA
Oncogene; 2015 Feb; 34(9):1073-82. PubMed ID: 24662818
[TBL] [Abstract][Full Text] [Related]
114. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
115. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
[TBL] [Abstract][Full Text] [Related]
116. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.
Hatzi K; Jiang Y; Huang C; Garrett-Bakelman F; Gearhart MD; Giannopoulou EG; Zumbo P; Kirouac K; Bhaskara S; Polo JM; Kormaksson M; MacKerell AD; Xue F; Mason CE; Hiebert SW; Prive GG; Cerchietti L; Bardwell VJ; Elemento O; Melnick A
Cell Rep; 2013 Aug; 4(3):578-88. PubMed ID: 23911289
[TBL] [Abstract][Full Text] [Related]
117. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.
Duy C; Hurtz C; Shojaee S; Cerchietti L; Geng H; Swaminathan S; Klemm L; Kweon SM; Nahar R; Braig M; Park E; Kim YM; Hofmann WK; Herzog S; Jumaa H; Koeffler HP; Yu JJ; Heisterkamp N; Graeber TG; Wu H; Ye BH; Melnick A; Müschen M
Nature; 2011 May; 473(7347):384-8. PubMed ID: 21593872
[TBL] [Abstract][Full Text] [Related]
118. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.
Caro P; Kishan AU; Norberg E; Stanley IA; Chapuy B; Ficarro SB; Polak K; Tondera D; Gounarides J; Yin H; Zhou F; Green MR; Chen L; Monti S; Marto JA; Shipp MA; Danial NN
Cancer Cell; 2012 Oct; 22(4):547-60. PubMed ID: 23079663
[TBL] [Abstract][Full Text] [Related]
119. Genome-wide Analysis Identifies Bcl6-Controlled Regulatory Networks during T Follicular Helper Cell Differentiation.
Liu X; Lu H; Chen T; Nallaparaju KC; Yan X; Tanaka S; Ichiyama K; Zhang X; Zhang L; Wen X; Tian Q; Bian XW; Jin W; Wei L; Dong C
Cell Rep; 2016 Feb; 14(7):1735-1747. PubMed ID: 26876184
[TBL] [Abstract][Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
